Zydus Group enters into in-licensing agreement with Neovii, Switzerland

To market transplant therapy - Grafalon

Zydus Group has entered into an in-licensing agreement with Neovii, a Switzerland based global bio-pharmaceutical company to launch Grafalon, an immunosuppressant extensively used in solid organ transplant and Stem Cell Transplant in India.

Zydus will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine.

Powered by Capital Market - Live News